[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363985-105":59,"doc-detail-363985-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","stemness-and-emt-profiles-shift-in-xenografts-derived-from-cisplatin-sensitive-and-cisplatin-tolerant-ovarian-cancer-cells-research-article","Stemness and EMT profiles shift in xenografts derived from cisplatin-sensitive and cisplatin-tolerant ovarian cancer cells - Research article","","Transcriptional changes driving epithelial-to-mesenchymal transition (EMT) in chemoresistant ovarian cancer remain debated, with evidence suggesting tumor cell plasticity and subclone reprogramming. The study established a cisplatin-tolerant model by dosing OVCAR-3 with cisplatin to generate OVCAR-3 CP. EMT profiling showed CP cells retained epithelial features and increased ALDH3A1, while parental cells displayed canonical mesenchymal markers and lacked stemness markers. After xenografting, both lines showed phenotypic plasticity, and parental xenografts gained EMT-like traits resembling cisplatin-tolerant tumors, supporting stemness-stem tolerance links.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/stemness-and-emt-profiles-shift-in-xenografts-derived-from-cisplatin-sensitive-and-cisplatin-tolerant-ovarian-cancer-cells-research-article/363985/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/stemness-and-emt-profiles-shift-in-xenografts-derived-from-cisplatin-sensitive-and-cisplatin-tolerant-ovarian-cancer-cells-research-article/363985.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were the cisplatin-tolerant OVCAR-3 CP cells generated?","Question",{"text":112,"@type":113},"OVCAR-3 cells were treated with a single dose of cisplatin to create the cisplatin-tolerant OVCAR-3 CP variant.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What EMT and stemness marker differences were observed between OVCAR-3 and OVCAR-3 CP cells?",{"text":117,"@type":113},"OVCAR-3 CP retained epithelial characteristics and showed elevated ALDH3A1, whereas parental OVCAR-3 expressed canonical mesenchymal markers (CDH2, VIM, ZEB1/2, SNAIL, SLUG) and lacked stemness marker expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What did xenografting reveal about phenotypic plasticity?",{"text":121,"@type":113},"After xenografting, both OVCAR-3 and OVCAR-3 CP exhibited phenotypic plasticity, and parental OVCAR-3 xenografts acquired EMT-like features resembling those seen in cisplatin-tolerant tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363985,1790194679,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","OPEN ACCESS  \nCitation: Mrkvicova A, Slavickova M, Peterova E, Melounkova L, Parova H, Havelek R, et al.  \n(2026) Stemness and EMT profiles shift in xenografts derived from cisplatin-sensitive and cisplatin-tolerant ovarian cancer cells. PLoSOne 21(2): e0342326. [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0342326](journal.pone.0342326)  \nEditor: Eric Asselin, Universite du Quebec a  \nTrois-Rivieres, CANADA Received: August 13, 2025  \nAccepted: January 21, 2026  \nPublished: February 5, 2026  \nCopyright: © 2026 Mrkvicova et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the manuscript and its Supporting  Information files.  \nFunding: This work was supported by the Cooperatio Program, research area DIAG and MH CZ-DRO (UHHK, 00179906) . The funders  \nRESEARCH ARTICLE  \nStemness and EMT profiles shift in xenografts derived from cisplatin-sensitive and cisplatintolerant ovarian cancer cells  \nAlena Mrkvicova1,2*, Marcela Slavickova2, Eva Peterova1, Lucie Melounkova1, Helena Parova2, Radim Havelek1, Anna Krejcova3, Renata Kohlerova1,  \nJana Nekvindova2, Petra Kazimirova1, Milena Hajzlerova1, Tomáš Rozkoš4, Martina Rezacova1  \n1 Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia, 2 Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czechia, 3 Department of Environmental and Chemical Engineering, Faculty of Chemical Technology, University of Pardubice, Czechia, 4 The Fingerland Department of Pathology, University Hospital Hradec Kralove, Hradec Kralove, Czechia  \n* [mrkvicovaa@lfhk.cuni.cz](mrkvicovaa@lfhk.cuni.cz)  \nAbstract  \nThe transcriptional alterations underlying epithelial-to-mesenchymal transition (EMT) in chemoresistant ovarian cancer remain a matter of debate, with emerging evidence pointing to tumour cell plasticity and subclone reprogramming. In this study, we developed a cisplatin-tolerant ovarian cancer model by treating the cisplatin-sensitive OVCAR-3 cell line with a single dose of cisplatin, generating the OVCAR-3 CP variant. These cisplatin-tolerant cells exhibited distinct EMT-related changes at both transcriptomic and protein levels, potentially regulated by epigenetic mechanisms. EMT profiling revealed that OVCAR-3 CP cells did not display a pronounced mesenchymal phenotype but rather retained epithelial characteristics and showed elevated expression of ALDH3A1 . In contrast, the parental chemosensitive OVCAR-3 cells expressed canonical mesenchymal markers (CDH2, VIM, ZEB1/2, SNAIL, SLUG) and lacked stemness marker expression. Upon xenografting, both OVCAR-3 and OVCAR-3 CP cells demonstrated phenotypic plasticity, with parental OVCAR-3 xenografts acquiring EMT-like features resembling to those observed in cisplatin-tolerant tumours. These findings suggest a decoupling of EMT from cisplatin-tolerance and instead underscore a stronger association between stemness traits and cisplatin tolerance. Our data further indicate that xenografting can induce significant cellular reprogramming. Comprehensive characterization of ovarian cancer cell-derived xenograft is therefore essential, as they represent a valuable translational platform for investigating therapy adapted ovarian cancer cells.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0342326](https://doi.org/10.1371/journal.pone.0342326) February 5, 2026 1 / 18  \nhad no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: NO.  \nIntroduction  \nChemoresistance remains a significant challenge in the treatment of ovarian cancer, often leading to treatment failure and disease p","cbCaiiykMi9jjIDu","https://ap.wps.com/l/cbCaiiykMi9jjIDu","pdf",1791013,18,"English","# Abstract\n## EMT and chemoresistance context\n## Cisplatin-tolerant model generation\n## EMT and stemness marker comparisons\n## Xenograft phenotypic plasticity and interpretation\n# Introduction\n## Chemoresistance mechanisms\n## Tumor heterogeneity and resistant states\n## EMT as a linked program","[{\"question\":\"How were the cisplatin-tolerant OVCAR-3 CP cells generated?\",\"answer\":\"OVCAR-3 cells were treated with a single dose of cisplatin to create the cisplatin-tolerant OVCAR-3 CP variant.\"},{\"question\":\"What EMT and stemness marker differences were observed between OVCAR-3 and OVCAR-3 CP cells?\",\"answer\":\"OVCAR-3 CP retained epithelial characteristics and showed elevated ALDH3A1, whereas parental OVCAR-3 expressed canonical mesenchymal markers (CDH2, VIM, ZEB1/2, SNAIL, SLUG) and lacked stemness marker expression.\"},{\"question\":\"What did xenografting reveal about phenotypic plasticity?\",\"answer\":\"After xenografting, both OVCAR-3 and OVCAR-3 CP exhibited phenotypic plasticity, and parental OVCAR-3 xenografts acquired EMT-like features resembling those seen in cisplatin-tolerant tumors.\"}]","Stemness and EMT profiles shift in xenografts derived from cisplatin-sensitive and cisplatin-tolerant ovarian cancer cells - Research article | PDF",1790154783,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d05451cf6a525a61f64001c529f2db7d.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dd166a9a7c6eb8a54b1b1534792e454.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2ce89b6fa17a750dde20cace5186b55.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a55ead8aed0f40f8a817572c6d3a57b2.webp",980,1268]